Company
Scenic Biotech
Treating neurodegeneration by restoring lysosomal function at its origin
Also known as Scenic Biotech B.V.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Headquarters
- Amsterdam, The Netherlands
- Legal name
- Scenic Biotech B.V.
- scenicbiotech.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Scenic Biotech is a neurometabolic company developing disease-modifying therapies that restore lysosomal function, a core driver of neurodegeneration. Its lead program, SC6177, a brain-penetrant small molecule, targets lysosomal dysfunction across genetic and age-related forms of neurodegeneration, with IND-enabling studies underway and first-in-human trials targeted for 2027.
Funding snapshot
- Total raised
- $31MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series A, $31M2022-03-11
Funding rounds
- Series A
- $31M2022-03-11, Announced
- Series A
- 2017-07-03
Products
- Web
- SC6177
Loading relationship preview